Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73621444" target="_blank" >RIV/61989592:15110/23:73621444 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/23:10157904

Výsledek na webu

<a href="https://www.mdpi.com/2075-1729/13/2/527" target="_blank" >https://www.mdpi.com/2075-1729/13/2/527</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/life13020527" target="_blank" >10.3390/life13020527</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

Popis výsledku v původním jazyce

Most patients suffering from Lyme disease are effectively treated with antibiotics. Insome patients, however, problems persist for a long time despite appropriate therapy. The termpost-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientificliterature. The pathogenesis is still not precisely known, but the involvement of immunopathologicalmechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositisspecific(MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory provenhistory of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting thecriteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoingdifferential diagnosis of neurological disorders without clinical and/or laboratory-proven history ofLyme disease. The presence of autoantibodies was determined by immunoblot methods and positivesamples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence ofmyositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5%of control subjects exhibiting no evidence of Lyme disease history. The difference was statisticallysignificant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positivesubjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raisedMSA/MAA autoantibodies formation in the group of PTLDS patients raising the question abouttheir involvement in the pathogenesis of this syndrome.

Název v anglickém jazyce

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome

Popis výsledku anglicky

Most patients suffering from Lyme disease are effectively treated with antibiotics. Insome patients, however, problems persist for a long time despite appropriate therapy. The termpost-treatment Lyme disease syndrome (PTLDS) is currently used for this condition in scientificliterature. The pathogenesis is still not precisely known, but the involvement of immunopathologicalmechanisms is assumed. In our study, we analyzed the presence of autoantibodies including myositisspecific(MSA) and myositis-associated autoantibodies (MAA) in patients with laboratory provenhistory of Lyme disease and with clinical symptoms of PTLDS. A total of 59 patients meeting thecriteria for PTLDS were enrolled in this study. The control group consisted of 40 patients undergoingdifferential diagnosis of neurological disorders without clinical and/or laboratory-proven history ofLyme disease. The presence of autoantibodies was determined by immunoblot methods and positivesamples were further tested for serum creatine kinase (CK) and myoglobin levels. The presence ofmyositis autoantibodies was detected in 18 subjects with suspected PTLDS (30.5%), but only in 5%of control subjects exhibiting no evidence of Lyme disease history. The difference was statisticallysignificant (p = 0.002). The subsequent biochemical analysis of muscle-damage markers in positivesubjects found a mild elevation in six MSA/MAA-positive PTLDS patients. The study detected raisedMSA/MAA autoantibodies formation in the group of PTLDS patients raising the question abouttheir involvement in the pathogenesis of this syndrome.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Life

ISSN

2075-1729

e-ISSN

2075-1729

Svazek periodika

13

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

527

Kód UT WoS článku

000940123400001

EID výsledku v databázi Scopus

2-s2.0-85148956065